BriaCell Therapeutics Corp. Quarterly Operating Income (Loss) in USD from Q3 2021 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
BriaCell Therapeutics Corp. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2021 to Q1 2024.
  • BriaCell Therapeutics Corp. Operating Income (Loss) for the quarter ending April 30, 2024 was -$9.23M, a 62.6% decline year-over-year.
  • BriaCell Therapeutics Corp. Operating Income (Loss) for the twelve months ending April 30, 2024 was -$35.3M, a 69.6% decline year-over-year.
  • BriaCell Therapeutics Corp. annual Operating Income (Loss) for 2023 was -$23.3M, a 52.2% decline from 2022.
  • BriaCell Therapeutics Corp. annual Operating Income (Loss) for 2022 was -$15.3M, a 119% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$35.3M -$9.23M -$3.55M -62.6% Feb 1, 2024 Apr 30, 2024 10-Q 2024-06-14
Q4 2023 -$31.7M -$9.83M -$5.34M -119% Nov 1, 2023 Jan 31, 2024 10-Q 2024-03-18
Q3 2023 -$26.4M -$8.5M -$3.1M -57.4% Aug 1, 2023 Oct 31, 2023 10-Q 2023-12-14
Q2 2023 -$23.3M -$7.71M -$2.47M -47.2% May 1, 2023 Jul 31, 2023 10-K 2023-10-25
Q1 2023 -$20.8M -$5.68M -$1.55M -37.7% Feb 1, 2023 Apr 30, 2023 10-Q 2024-06-14
Q4 2022 -$19.2M -$4.49M -$840K -23% Nov 1, 2022 Jan 31, 2023 10-Q 2024-03-18
Q3 2022 -$18.4M -$5.4M -$3.12M -136% Aug 1, 2022 Oct 31, 2022 10-Q 2023-12-14
Q2 2022 -$15.3M -$5.23M May 1, 2022 Jul 31, 2022 10-K 2023-10-25
Q1 2022 -$4.12M Feb 1, 2022 Apr 30, 2022 10-Q 2023-06-14
Q4 2021 -$3.65M Nov 1, 2021 Jan 31, 2022 10-Q 2023-03-16
Q3 2021 -$2.28M Aug 1, 2021 Oct 31, 2021 10-Q 2022-12-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.